投资要点 ❑ 泡泡玛特发布 25Q1 业务状况 25Q1 收入同增 165-170%，环比加速（24H2 收入同增 143%），中国收入同增 95- 100%（24H2 收入同增 70.4%），海外同增 475-480%（24H2 收入同增 438%） 证券研究报告 | 公司点评 | 文娱用品 泡泡玛特(09992) 报告日期：2025 年 04 月 28 日 新品火爆接力，业绩再超预期，加速迈向"世界的泡泡玛特" ——泡泡玛特 25Q1 业务点评 ❑ 国内外均加速，新品火爆接力，IP 全球势能强化 中国：25Q1 线下收入同增 85-90%，线上同增 140-145%，店效环比再提升，多品爆 火，哪吒 2 盲盒爆火后，LABUBU 航海王联名盲盒、LABUBU 象棋大冒险毛绒、 DIMOO 迪士尼联名毛绒等持续接力，多业态贡献增量（小野品牌店/饰品快闪店）。 海外：25Q1 收入同增 475-480%，其中：1）亚太收入同增 345-350%（24H2 同增 413%）,东南亚景气延续，以泰国为中心蔓延邻国，电商高增；2）美洲收入同增 895-900%（24H2 同增 649%），美国加速开店且位置更优，预 ...

证券研究报告 卫龙美味 (9985 HK) 港股通 魔芋开启新纪元，辣味王者再启航 华泰研究 首次覆盖 2025 年 4 月 28 日│中国香港 食品 首次覆盖卫龙美味并给予"买入"，目标价 19.96 港元（基于 25 年 32xPE）。 中国零食行业在较长时间内呈现多品类、弱品牌的特点，辣味零食成瘾性更 强、复购率更高，有效延长产品生命周期。卫龙已成功打造国民辣条品牌形 象、领先优势明显，并作为魔芋赛道的先行者、有望率先享受品类高速扩张 的红利。卫龙根基稳固，品牌力构成竞争力的核心，并具备开创创新品类的 定力与能力，敢为人先、勇于求变，后续或仍将聚焦打造大单品+拥抱新渠 道，有望突破零食行业产品生命周期短、渠道结构多变两大痛点。 行业层面：辣条品类规模稳定，魔芋品类蓬勃发展 辣味零食赛道高景气、强粘性。1）辣条品类：据尼尔森，品类销售体量~100 亿，市场规模稳定，头部品牌显露，据马上赢，23 年卫龙市占率达 28%。 2）魔芋品类：公众健康意识崛起、独特的口感与高性价比之下，魔芋品类 蓬勃发展，中国 24 年魔芋食品出厂口径市场规模~70 亿（据盐津铺子公众 号），年增长 20%+，考虑魔芋的受众较辣条 ...

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 57.27, based on a closing price of HKD 49.40 [6]. Core Insights - The report emphasizes that Leap Motor's success is driven by its commitment to self-research and development, leading to a strong product strategy that has helped the company stand out in the competitive market [2][15]. - Leap Motor achieved its first quarterly profit in Q4 2024, with a net profit of RMB 0.8 billion, marking it as the second profitable new energy vehicle manufacturer [3][46]. - The strategic partnership with Stellantis is highlighted as a significant advantage for Leap Motor's overseas expansion, providing unique resources and market access [4][46]. Summary by Sections 1. Self-Research and Product Strategy - Leap Motor has focused on self-research since its establishment in 2015, mastering a super-integrated technology architecture, which has been upgraded to LEAP 3.5 in 2025 [2][15]. - The company targets the mainstream passenger car market priced between RMB 100,000 and 200,000, with a projected total delivery of nearly 300,000 vehicles in 2024, ranking among the top three in new energy vehicle brands [2][21]. - Three key success factors are identified: efficient launch of range-extended models, continuous upgrades of existing models, and excellent cost control leading to competitive pricing [2][3][15]. 2. Profitability and Future Outlook - Leap Motor's revenue for 2024 reached RMB 32.16 billion, a year-on-year increase of 92%, with a gross margin of 8.4% [3][46]. - The company expects sustainable profitability due to a rich new vehicle planning and strong channel capabilities, which are anticipated to drive continuous sales growth [3][46]. - The report forecasts revenues of RMB 60.5 billion, RMB 80.5 billion, and RMB 106.8 billion for 2025, 2026, and 2027 respectively, with net profits projected to reach RMB 0.69 billion, RMB 22.52 billion, and RMB 43.92 billion in the same years [5][8]. 3. Overseas Business Development - The partnership with Stellantis, a major global automotive group, is expected to enhance Leap Motor's overseas business prospects significantly [4][46]. - The collaboration allows Leap Motor to leverage Stellantis's extensive dealer network and manufacturing resources, facilitating rapid market expansion in Europe and South America [4][46]. - The report suggests that local production could significantly improve profitability by reducing export costs and replicating successful domestic production practices [4][46].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [4]. Core Insights - The company is expected to experience significant revenue growth driven by its AI Agent initiatives, with projected revenues of 2.335 billion, 2.962 billion, and 3.684 billion CNY for 2025, 2026, and 2027 respectively [4]. - The company is recognized as a global leader in marketing and sales SaaS platforms, maintaining rapid growth and a strong market position [5][17]. - The marketing and sales SaaS market in China is projected to grow significantly, with a compound annual growth rate (CAGR) of 29.3% from 2022 to 2027, indicating a substantial opportunity for the company [6][50]. Summary by Sections 1. Company Overview - The company, founded in 2009, has launched key SaaS products including T Cloud for SMB clients and Zhenke for KA clients, serving over 200,000 enterprises across various industries [5][17]. - The company has a stable shareholding structure and an experienced management team, with the founders holding approximately 45.63% of the shares [41][42]. 2. Market Potential - The marketing and sales SaaS market in China is currently underpenetrated, with a projected market size increase from 206 billion CNY in 2022 to 745 billion CNY by 2027 [6][50]. - The company is the largest provider of marketing and sales SaaS solutions in China, with a market share of 2.6% in 2022 [55][56]. 3. AI Agent Integration - The company is embracing AI Agent technology, which is expected to revolutionize the SaaS industry by shifting value assessment from software usage to business outcomes [7][70]. - The AI Agent market in China is anticipated to reach 3.3 trillion CNY by 2028, highlighting the transformative potential of AI in marketing and sales [74][82]. 4. Financial Projections - The company's revenue is projected to grow from 1.232 billion CNY in 2023 to 2.334 billion CNY in 2025, with a year-over-year growth rate of 49.8% [9]. - The net profit is expected to improve from a loss of 0.33 billion CNY in 2025 to a profit of 3.21 billion CNY by 2027 [4][9].

Investment Rating - The report assigns a "Buy" rating for China Ping An Insurance (2318 HK) with a target price of HKD 60.00, indicating a potential upside of 30.6% from the current price of HKD 45.95 [1][10]. Core Insights - The report highlights stable growth in operating profit and an unexpected increase in new business value, with a 34.9% year-on-year growth in new business value driven by various channels [5][11]. - The report notes a significant decline in net profit, down 26.4% year-on-year, primarily due to investment losses and a one-time valuation drop from the consolidation of Ping An Good Doctor [5][11]. - The report emphasizes improvements in the comprehensive cost ratio for property and casualty insurance, which decreased by 3 percentage points year-on-year to 96.6% [5][11]. - The solvency position is strong, with a core solvency ratio of 163.7%, up 47.3 percentage points from the end of 2024 [5][11]. Financial Overview - Revenue is projected to grow from RMB 913,789 million in 2023 to RMB 1,057,335 million in 2025, reflecting a compound annual growth rate (CAGR) of approximately 7.5% [4][11]. - Net profit is expected to recover from RMB 85,665 million in 2023 to RMB 120,657 million in 2025, with a notable increase of 47.8% in 2024 [4][11]. - The report forecasts earnings per share (EPS) to be RMB 6.95 in 2024 and RMB 6.63 in 2025, with a projected price-to-earnings (P/E) ratio of 6.5 in 2025 [4][11]. Business Performance - The first quarter of 2025 saw a 2.4% year-on-year increase in operating profit after tax (OPAT), primarily from the life and health insurance segments, while property and casualty insurance and banking segments experienced declines [5][11]. - The new business value rate improved significantly, reaching 28.3%, an increase of 11.4 percentage points year-on-year, attributed to product structure optimization and cost reduction measures [5][11]. - The average daily trading volume of the stock is reported at 50.03 million shares, with a market capitalization of approximately HKD 924.92 billion [3][11].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 61.59 per share, compared to the current price of HKD 37.85 [6]. Core Insights - The company is entering a harvest period for its innovation and internationalization efforts, following significant progress in its pipeline and global expansion after privatization [1]. - The company has achieved historical profitability in the first half of 2023, with a revenue of HKD 25.01 billion, marking a year-on-year increase of 93.9% [6][25]. - The innovative drug segment, particularly the differentiated PD-1 drug, is expected to drive significant revenue growth in the medium term [4][6]. Summary by Sections 1. Commercialization and Innovation - The company has established itself as a pioneer in biosimilars, with its first product, Rituximab, approved in 2019, and is now focusing on expanding its innovative drug portfolio [14][15]. - The revenue from biosimilars reached HKD 36.3 billion in 2024, while the innovative drug segment generated HKD 13.1 billion, accounting for 22.86% of total sales [29]. 2. HLX43: Potential in PD-L1 ADC - HLX43 is the second PD-L1 ADC drug to enter clinical trials globally, showing significant potential as a future pillar in the company's pipeline [2]. - The drug is currently in clinical phase II and has demonstrated promising data, indicating a strong confidence from the company in its development [2]. 3. HLX22: Potential to Change HER2 Positive Gastric Cancer Treatment - HLX22 has shown superior clinical benefits compared to standard treatments in HER2 positive gastric cancer, with ongoing international phase III trials [3]. - The drug has received orphan drug designation in the US, highlighting its potential in the gastric cancer treatment landscape [3]. 4. Differentiated PD-1 Drug: Surulitinib - Surulitinib is positioned to address unmet clinical needs in small cell lung cancer, with expected rapid market uptake upon approval [4]. - The drug has shown optimal data in clinical trials, indicating a strong commercial potential in various indications [4]. 5. Internationalization and Market Expansion - The company has a strong track record in internationalization, with significant licensing agreements and expected revenue growth from overseas markets starting in 2025 [5]. - The company aims to leverage its first-mover advantage in biosimilars and innovative drugs to maximize market value domestically and internationally [5]. 6. Profit Forecast - Revenue projections for 2025-2027 are estimated at HKD 58.73 billion, HKD 59.70 billion, and HKD 71.25 billion, with corresponding net profits of HKD 8.27 billion, HKD 7.97 billion, and HKD 11.22 billion [6]. - The company is expected to continue its upward trajectory in profitability, driven by its innovative pipeline and effective cost management strategies [6][32].

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company demonstrates strong operational resilience, with a high dividend yield leading to a potential revaluation of its value [1] - The privatization transaction is progressing normally, with the current stock price implying a potential discount of 41% for the company's H shares [4] - The expected dividend yield for 2025 is 5.4% [1] Summary by Relevant Sections Retail Gas Volume - In Q1 2025, the company achieved retail gas volume of 7.258 billion cubic meters, a year-on-year increase of 0.3%, outperforming the national natural gas consumption growth rate of -2.2% [2] - The company expects a 6% year-on-year growth in gross profit from retail gas in 2025 [2] Comprehensive Energy Sales - The company reported a comprehensive energy sales volume of 10.039 billion kWh in Q1 2025, a year-on-year increase of 9.9% [3] - The expected gross profit growth for comprehensive energy in 2025 is projected to be 12% [3] Smart Home Services - The penetration rate for smart home services reached 3.7% in Q1 2025, a decrease of 0.3 percentage points year-on-year [3] - The expected gross profit growth for smart home services in 2025 is projected to be 10% [3] Financial Forecasts - The company slightly adjusted its profit forecasts, with core profits for 2025-2027 expected to be 7.220 billion, 7.655 billion, and 8.039 billion RMB respectively, reflecting a CAGR of 5% over three years [5] - The target price has been slightly revised down to 68.6 HKD, based on a 10x PE for 2025E [5] Key Financial Metrics - The company’s revenue for 2025 is projected at 113.873 billion RMB, with a year-on-year growth of 3.66% [6] - The expected EPS for 2025 is 6.38 RMB [6]

证券研究报告 新高教集团 (2001 HK) 基本面依然稳健，关注新校拓展 | 华泰研究 | | | 更新报告 | | --- | --- | --- | --- | | 2025 年 | 4 月 | 27 日│中国香港 | 高等教育 | 新高教集团公布 FY25H1 业绩：公司实现主营业务收入 14.13 亿元， yoy+7.8%，占我们全年预测的 54%，我们认为基本符合预期；经调整净利 润 4.56 亿元，yoy+7.0%，占我们全年预测的 57%，略超预期。上半年资本 开支 3.93 亿元，支出节奏符合全年指引（8-9 亿元）。公司旗下现有学校学 历提升申报工作稳步推进，并宣布将在海南合作筹办一所本科及以上学历层 次的高等教育机构，进一步扩大校网。我们认为公司在学历提升的转型期基 本面仍然保持稳健增长，高等学历教育收入和利润稳定性强，看好长期可持 续内生增长，维持"买入"评级。 招生竞争力持续增强，生源结构进一步优化 得益于持续的教学硬件、师资、就业质量投入，FY25H1 公司旗下院校排名 大幅提升，云南/甘肃/华中学校分别在校友会 2025 全国民办大学排行榜提 升 1/8/7 名，贵州/洛阳/郑州 ...

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company demonstrates strong operational resilience, with a high dividend yield leading to a potential revaluation of its value [1] - The privatization transaction is progressing normally, with the current stock price implying a potential discount of 41% for the company's H shares [4] Summary by Sections Sales and Revenue - In Q1 2025, the company achieved a total gas sales volume of 7.258 billion cubic meters, representing a year-on-year increase of 0.3%, outperforming the national natural gas consumption growth rate of -2.2% [2] - The company expects a 6% year-on-year growth in gross profit for retail gas in 2025 [2] Energy Sales and Smart Home Services - The company reported a 9.9% year-on-year increase in comprehensive energy sales volume, reaching 100.39 billion kWh in Q1 2025 [3] - The penetration rate for smart home services decreased to 3.7%, with a year-on-year decline of 0.3 percentage points [3] - The company anticipates a gross profit growth of at least 10% for smart home services in 2025 [3] Financial Projections - The company slightly adjusted its profit forecasts, with core profits for 2025-2027 expected to be 7.220 billion, 7.655 billion, and 8.039 billion RMB, respectively [5] - The target price is set at 68.6 HKD, based on a 10x 2025E PE ratio [5] Key Financial Metrics - The company is projected to have a revenue of 113.873 billion RMB in 2025, with a year-on-year growth of 3.66% [6] - The expected EPS for 2025 is 6.38 RMB, with a projected ROE of 15.32% [6]

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 61.59 per share, maintaining the rating from previous assessments [6]. Core Views - The report emphasizes that the company is entering a harvest period for its innovation and internationalization efforts, following significant progress in its pipeline and global expansion after privatization [1]. - The company has achieved historical profitability in the first half of 2023, with a notable increase in revenue and net profit, indicating strong growth potential [6][25]. Summary by Sections 1. Commercialization and Innovation - The company has established itself as a pioneer in biosimilars, with its first product, Rituximab, being the first biosimilar approved in China [14]. - The company is focusing on innovative drugs and has seen significant sales growth, with projected revenues of HKD 57.24 billion in 2024, reflecting a year-on-year increase of 6.06% [25][29]. 2. HLX43: PD-L1 ADC Development - HLX43 is the second PD-L1 ADC to enter clinical trials globally, showing promising potential for treating patients who do not respond to PD-1/PD-L1 therapies [2]. - The report highlights the urgent clinical need for effective treatments in EGFR wild-type NSCLC, where current therapies primarily rely on chemotherapy [37]. 3. HLX22: HER2 Positive Gastric Cancer - HLX22 has demonstrated significant clinical benefits in treating HER2 positive gastric cancer, with ongoing international trials expected to enhance its market position [3]. - The drug has received orphan drug designation in the US, indicating its potential as a key revenue driver for the company [3]. 4. Differentiated PD-1 SruLi monoclonal antibody - The company is advancing its differentiated PD-1 monoclonal antibody, SruLi, targeting unmet clinical needs in small cell lung cancer, with expected revenue of HKD 13.13 billion in 2024 [4]. - The report notes that SruLi has shown superior efficacy in clinical trials compared to existing treatments, positioning it for rapid market uptake [4]. 5. Internationalization and Market Expansion - The company has a strong track record in internationalization, with successful licensing agreements and product approvals in various global markets [5]. - The anticipated approval of SruLi in Europe and the US is expected to drive overseas revenue growth starting in 2025 [5]. 6. Financial Forecast - The company is projected to achieve revenues of HKD 58.73 billion, HKD 59.70 billion, and HKD 71.25 billion for the years 2025 to 2027, with corresponding net profits of HKD 8.27 billion, HKD 7.97 billion, and HKD 11.22 billion [6]. - The report indicates a significant improvement in the company's financial health, with a historical achievement of breakeven in 2023 [6][25].